438239-16-8

Basic information

• Product Name: 2-chloro-5-[5-({1-[4-(ethoxycarbonyl)phenyl]-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene}methyl)-2-furyl]benzoic acid
• Synonyms: 2-chloro-5-[5-({1-[4-(ethoxycarbonyl)phenyl]-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene}methyl)-2-furyl]benzoic acid
• CAS NO: 438239-16-8
• Molecular Formula: C25H19ClN2O6
• Molecular Weight: 478.88116
• Mol File: 438239-16-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-chloro-5-[5-({1-[4-(ethoxycarbonyl)phenyl]-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene}methyl)-2-furyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-[5-({1-[4-(ethoxycarbonyl)phenyl]-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene}methyl)-2-furyl]benzoic acid(438239-16-8)
• EPA Substance Registry System: 2-chloro-5-[5-({1-[4-(ethoxycarbonyl)phenyl]-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene}methyl)-2-furyl]benzoic acid(438239-16-8)

Safety Data

• Hazardous Substances Data: 438239-16-8(Hazardous Substances Data)

Upstream product

• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 355142-36-8 2-chloro-5-(5-formylfuran-2-yl)benzoic acid 
• 107430-36-4 ethyl 4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoate 
• 24589-77-3 4-hydrazinobenzoic acid hydrochloride 
• 60875-16-3 4-(3-methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid 

Relevant articles and documents

XPA INHIBITOR COMPOUNDS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

KU INHIBITORS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.